ISRCTN ISRCTN84503751
DOI https://doi.org/10.1186/ISRCTN84503751
Secondary identifying numbers 15819
Submission date
18/03/2015
Registration date
19/03/2015
Last edited
25/04/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
The most common cause of loss of vision in diabetes is macular oedema. Diabetes can cause a condition called retinopathy where high blood glucose levels cause damage to the tiny blood vessels lining the surface of the back of the retina. This can result in the growth of new, abnormal blood vessels which may leak blood or fluid into the eye. If this happens in the most sensitive region of the retina, the macula, it causes the area to swell (oedema). Over time, this can lead to scarring and loss of vision. Ranibizumab is a drug used to treat diabetic macular oedema. It is given as an injection into the eye. Whilst it can work well, a large number of injections may be needed over a number of years. Ranibizumab works by preventing the growth of abnormal blood vessels. It is thought that macular oedema is mainly caused by changes in the central blood circulation in the retina. However, it is possible that poor circulation in the peripheral areas of the retina (peripheral ischemia) can lead to an increase in vascular endothelial growth factor (VEGF) levels (a protein that stimulates the growth of blood vessels) which may result in the recurrence of macular oedema, at least in a subset of patients. It has only recently become possible to visualize the degree of peripheral ischaemia with an imaging technique called widefield fluorescein angiography (wFFA). It is therefore possible to target the area of ischaemia with a laser that might reduce VEGF levels and stabilize macular oedema, making the treatment more acceptable for patients, more cost effective and lead to better long term visual results. The aim of this study is to compare the treatment of macular oedema and peripheral ischaemia with a combination of ranibizumab and retinal laser treatment with ranibizumab alone.

Who can participate?
Adults with macular oedema caused by diabetic retinopathy.

What does the study involve?
Participants are randomly allocated into one pf two groups. Those in group 1 are treated with
ranibizumab and retinal laser treatment. Those in group 2 are treated only with the ranibizumab. The treatments are assessed in terms of how long it is before each participant needs a repeat ranibizumab injection, number of injections needed in a year and the participants visual acuity (acuteness/clearness of vision) after a year.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Newcastle upon Tyne Hospitals NHS Trust (UK)

When is the study starting and how long is it expected to run for?
April 2014 to December 2015

Who is funding the study?
Novartis Pharmaceuticals UK Limited

Who is the main contact?
Mr Sean Scott

Contact information

Mr Sean Scott
Scientific

Newcastle upon Tyne Hospitals NHS Trust
Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
United Kingdom

Study information

Study designRandomised; Interventional; Design type: Not specified, Treatment
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a patient information sheet
Scientific titleRandomized trial of widefield guided PRP for diabetic macular oedema (DMO) treated with ranibizumab
Study acronymRDP
Study objectivesRanibizumab is licensed for the treatment of diabetic macular oedema. It is given as an injection into the eye. Whilst it can work well a large number of injections may be needed over a number of years. Ranibizumab works by blocking vascular endothelial growth factor (VEGF). The main pathology causing the oedema maybe due to changes in the central retinal circulation but it is possible that peripheral ischaemia, which is a poor circulation in the peripheral areas of the retina, leads to an increase in VEGF levels and so drives the recurrence of macular oedema, at least in a subset of patients. It has only recently become possible to visualize the degree of peripheral ischaemia with widefield fluorescein angiography (wFFA). It is therefore possible to target the area of ischaemia with peripheral laser that might reduce VEGF levels and so help lead to stabilization of the macular oedema and so make the treatment more acceptable for patients, more cost effective and lead to better long term visual results. In this study patients with macular oedema and peripheral retinal ischaemia will be treated with ranibizumab but randomized to additional retinal laser. The main outcomes will be the length of time a patient does not require an injection, after the initial loading phase. Number of injections in a year and the difference in visual acuity at the end of one year.
Ethics approval(s)13-NE-0197
Health condition(s) or problem(s) studiedTopic: Diabetes, Ophthalmology; Subtopic: Both, Eye (all Subtopics); Disease: Retinopathy, Ophthalmology
InterventionPatients with OCT confirmed DMO and wFFA confirmed peripheral retinal ischaemia will be randomised to PRP + Ranibizumab or Ranibizumab monotherapy as per pre-defined criteria.
Study Entry : Single Randomisation only
Intervention typeProcedure/Surgery
Primary outcome measureNumber of repeat Ranibizumab injections required after the first 6 months up until one year post treatment
Secondary outcome measures1. Length of treatment free interval
2. Difference in visual acuity at one year
3. Difference in time
Overall study start date01/04/2014
Completion date31/12/2015

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsPlanned Sample Size: 70; UK Sample Size: 70
Key inclusion criteria1. Visual acuity 20/30 to 20/300
2. Macular oedema secondary to diabetic retinopathy. (OCT Thickness of >300 micrometres central subfield, on spectral domain OCT (Spectralis OCT Heidelberg engineering)
3. EDTRS grade 53 – 57 up to non high-risk proliferative diabetic retinopathy
4. Peripheral ischaemia seen on wFFA
5. Patient able to give consent and take part in all study procedures
6. In the opinion of the investigator the patient should benefit from treatment
Key exclusion criteria1. Visual acuity worse than 20/300
2. Rubeosis
3. Proliferative retinopathy with high risk characteristics
4. Unable to give consent or take part in all study procedures
5. Other conditions that might interfere with the assessment of the eye such as cataract or prevent the macular oedema from settling such as vitreomacular traction, epiretinal membrane, to a degree that would in the opinion of the investigator affect response to treatment; conditions that would prevent the visual acuity improving such as foveal atrophy, uveitis
6. Previous macular laser within 3 months in the study eye
7. Previous peripheral (PRP) laser in the study eye
8. Previous injection therapy within last 4 months (anti VEGF) 6 months (steroid) in the study eye
9. Pregnant
10. Uncontrolled systemic illness that in the opinion of the investigator would preclude involvement
11. Cataract or other intraocular surgery within 3 months
12. Previous vitrectomy
Date of first enrolment01/04/2014
Date of final enrolment31/12/2015

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Newcastle upon Tyne Hospitals NHS Trust
Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
United Kingdom

Sponsor information

Newcastle upon Tyne Hospitals NHS Foundation Trust
Hospital/treatment centre

Claremont Wing
Royal Victoria Infirmary
Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
England
United Kingdom

ROR logo "ROR" https://ror.org/05p40t847

Funders

Funder type

Industry

Novartis Pharmaceuticals UK Limited
Private sector organisation / For-profit companies (industry)
Alternative name(s)
Novartis UK, NOVARTIS UK LIMITED
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 06/02/2019 25/04/2023 Yes No

Editorial Notes

25/04/2023: Publication reference added.
19/01/2018: No publications found, verifying study status with principal investigator.